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Abstract 
Fostering excitement in pharmacy student learning can be achieved through reinforcing drug therapies in curricular 
and extracurricular endeavors. This paper described an extracurricular initiative that elevated awareness of drug 
therapy in its current, future, and past members. This process occurred on an annual basis. Upon invitation, 
participants were expected to attend meetings with current and graduate organizational members. These settings 
provided opportunities for recognition and remembrance of organizational history and drug therapies. Checkpoints 
were inserted to verify progression towards full membership. The primary role of graduate members in this process 
was the yielding of their professional insights. A student – led, peer – facilitated model of drug therapy exposure 
along these lines resonates with calls for increased innovative learning strategies. 
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Introduction 
The rigor of pursuing a doctorate of pharmacy (PharmD) degree often manifests as attempts to 
absorb voluminous amounts of material in relatively short time periods. To increase the likelihood of 
success, information acquisition should serve as a prelude to evaluation and application of significance. 
Predicated upon a student’s pre-existing educational strengths and areas requiring improvement prior to 
entry into professional school, these analytical skills may be deficient and result in suboptimal scholastic 
performances. The challenge of pharmacy curricula navigation is further compounded when allotting for 
personal concerns that may compound stress levels. Surmounting the multifaceted demands that 
predestine pharmacy school survival may necessitate embracing peer support groups or organizational 
involvement that ideally supply academic and emotional stability.       
Corporate accountability among pharmacy students should extend to both academic and non-
academic sectors. In fact, some teachable moments rely more heavily upon interpersonal interactions that 
transcend the classroom setting. Student involvement in extracurricular activities at various stages in the 
educational process has been shown to foster more robust learning experiences.  
Participation demands a healthy level of commitment while challenging time management skills. 
Students are charged to work with peers in a largely self-governance capacity. These undertakings often 
encompass navigating personal and professional misgivings that can surface in different settings.  
A sizeable portion of pharmacy students’ extracurricular pursuits originate from student 
organizations featured at schools and colleges of pharmacy. The bulk of their activities are engineered to 
sustain community viability wherein the institution is housed. While attention to external edification is 
encouraged, there is a paucity of literature detailing student organizational attempts to enact longitudinal 
scholastic modalities internally. The purpose of this paper is to describe a student pharmacy organization’s 
novel approach to continual drug therapy reinforcement and to elaborate upon implications of its 
innovation. 
 
Methods 
Kappa Psi Pharmaceutical Fraternity, Incorporated (Kappa Psi) is an international pharmacy 
organization that features institutional – specific offerings, denoted as chapters, at selected schools and 
colleges of pharmacy. Kappa Psi membership is normally available to pharmacy students seeking entry 
into the chapter described herein within their first or second professional year of matriculation. The 
minimal grade point average (GPA) threshold for participation is traditionally 2.5 on a 4.0 scale. A general 
depiction of the steps that precede participation in the membership intake process can be found in Figure 
1. The membership intake process, which can also be referred to as pledging, at the chapter described 
herein, often involves querying of past and present accomplishments of the organization. This approach 
is accompanied by requests of pledges (aspiring members) to compare and contrast attributes of current 
chapter members. A mark of distinction for chapter members is the receipt of specific pledge class names 
acquired during their pledging process. While the assigning of pledge class names is not exclusive to the 
Kappa Psi chapter being described here, the nature of the names is unique.  
The intake process, typically occurring once per academic year, and approximating 90 days in 
duration, is arranged by invitation only and can be summarized in Figure 2. This timeframe reflects 
calendar days, as opposed to working business days. Receipt of a predetermined pledge name is a ritual 
that signifies pledging termination. The yielded nomenclature also cements the legacy of newly added 
members in the annals of the chapter’s history. Subsequent Kappa Psi pledges, in turn, are charged to 
learn the pledge class names that preceded them and the rationales behind their rendering.  
The novelty of the pledge names generated by the chapter described herein is that they primarily 
assume drug therapy names (DTNs). In a minority of cases, actual DTNs are not assigned but rather drug 
therapy aspects. The decision as to whether to issue a brand or generic name is often made 
indiscriminately. These DTNs are supplied to each pledge class member at the conclusion of the intake 
process based largely upon the characteristics he or she exhibited during the specified time period. Current 
members of the chapter often have pre-existing knowledge of pledges’ personas prior to official interest 
in membership being declared. Therefore, these anecdotes may also factor into the selection of pledge 
names.  
An example of the significance associated with a DTN can be observed by the receipt of 
phenobarbital. It can be decided by the current members of the chapter that the pledge exhibited sedating 
properties (boring and unenthused) initially during the pledge process. However, progression was made 
which was evinced by his or her contributions as an antiepileptic (stabilizing) force for fellow pledge 
class members. After receiving approval from the faculty advisor to the organization, the DTNs are 
dispensed on behalf of the current members without any consultation with the targeted individuals. 
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Disagreements regarding the merits of the assigned DTN on behalf of the recipient (new members) are 
silenced by the prerogatives of the current members (older members).   
Traditionally, a maximum or minimum number of pledges are not imposed upon the intake 
process. A list of the DTNs generated from 2004 through 2014 can be found in Table 1 and Table 2. The 
order of the DTNs as they appear in the pledge class lists are not based upon perceived clinical importance. 
Rather, officers of the pledge class, i.e., president, vice-president, secretary, treasurer, which are elected 
by their pledge class peers, are represented at the beginning. The sequencing of the balance of the DTNs 
is determined by height considerations in an ascending fashion. Occurrences where slots are missing 
associated DTNs (denoted by -----) are indicative of individuals that discontinued the intake process early.  
Weekly reviews, typically approximating 60 to 90 minutes in length, are incorporated by the 
current membership as recurring showcases for pledges to display mastery of the previously assigned 
DTNs, rationales, and history of the organization. Graduate members of the organization are also 
encouraged to return to the weekly sessions and actively participate in the proceedings. In preparation for 
the weekly meetings, pledge class members often coordinate independent study periods where greater 
opportunities for reiteration take place. The time designated to these study periods outside of the weekly 
meetings is loosely regulated by the current membership. Striking a balance between rehearsing for 
weekly sessions and accommodating other compelling demands, e.g., employment, studying for didactic 
examinations, is entrusted to the discretion of the aspiring members. 
 
Results 
The 165 pledge class names spanning from 2004 – 2014 can be found in Table 1 and Table 2. 
Twelve pledges did not complete the process and therefore weren’t assigned DTNs. Thirteen duplicate 
and two triplicate representations of DTNs featured during the 10 year period were observed. A drug 
information software product13 was used to aid in the detection of redundancies through the identification 
of the same brand names, drug therapies having their brand and generic names portrayed, and different 
brand names corresponding to a common generic designation. No repeated references to drug therapies 
were isolated within a specific pledge class. As a result, 145 (87.9%) reflects the summation of pledge 
class names appearing only once.  
The total number of brand and generic names observed among the listings were 78 and 65, 
respectively. No more than one therapeutic class was shown to be represented within each pledge class. 
A lack of certainty did accompany some therapeutic appellations assigned. For example, instances of 
nonspecific titles such as “vaccine” or “multivitamins” did surface (Table 1 and Table 2). Agents 
possessing controlled release properties were in the minority. Four drug products were associated with 
extended release properties.  
Eight names were found to be non-medicinal products (Table 1 and Table 2).  One therapeutic 
agent was provided as a DTN five years after its removal from the market (Table 1). Two additional 
names are not approved for use within the United States of America (Table 2). Notable trends in the 
provision of drug names over time were undetectable. 
 
Discussion 
Immersion of pharmacy students in medication inquiry through extracurricular means offers 
promising considerations. Perpetual exposure to therapeutic knowledge is in concert with the “improve 
my professional knowledge and competence” clause admonished in the “Oath of a Pharmacist”. Trainings 
that expand beyond classroom confinements can be regarded as influential encounters. Learning in these 
instances has the tendency to lose a degree of inhibition and stimulate creative approaches for delivery 
and reception.  
Peer facilitated efforts often amplify the fulfilment derived from educational exchanges and may 
venture to establish fondness among participating parties. 
Kappa Psi Pharmaceutical Incorporation commonly touts its affinity for internal sustainment and 
external appeal. Intricacies of the intake process described here help to substantiate these interests. 
Conveyances by student members of DTNs to recipients along with their accompanying rationales are 
fruitful. A platform exists for greater acquaintance with prospective members and more exposure to drug 
therapy information. Serendipitously, study sessions emerge from efforts to bestow creative names upon 
future members.  
The absence of limitations on the number of pharmacy students invited to participate in the intake 
process is compelling. Directly proportional relationships between the number of students invited to 
participate and the corresponding drug names dispensed are prone to equate to improved familiarity with 
medication therapies. While multiple occurrences of repetitive drug names were identified, an estimation 
is that these redundancies evolve into reinforcement strategies that translate positively on formative 
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assessments. Students enrolling in pharmacy school and subsequently joining the organization later 
perceivably have an advantage from a drug knowledge acquisition standpoint due to an increased volume 
of therapies encountered. While parameters on the timeframe that pharmacy student pledges are required 
to learn previous members’ drug names is not routinely established for the administering institution, 
adoption in other environments may elect to narrow the scope.   
Engagement by graduate members in the weekly sessions is also impactful. Their presence 
affords expanded capacity for mentorship to current students in dual respects. First, their anecdotes 
surrounding optimally navigating the pharmacy curriculum are often well received. Secondly, primarily 
functioning as practicing pharmacists, their professional experiences usually place the myriad of drug 
names that are disseminated and memorized into appropriate clinical contexts. Equally as important, 
graduate members are invariably employed in numerous facets of the profession of pharmacy. Therefore, 
diversity in scopes of practice may not allow for frequent utilization of each drug therapy discussed at the 
weekly meetings. As a result, graduate member attendance at the weekly meetings can serve as informal 
and ostensible continuing education reciprocities.   
Opportunities exist to augment this process at other institutions aspiring to replicate this model. 
In addition to seeking approval of the DTNs, student members can appeal to their faculty advisors to craft 
a review session to further discuss therapeutic value of the agents in view. Limitations to this arrangement 
do exist.  
The faculty advisor may lack the comfort to coordinate a session along these lines. Moreover, 
considering approaches to therapy selection, modification, and maintenance can be largely experience – 
based, faculty members responsible for formal delivery of the drug therapy information and the faculty 
advisor (if the individual is different) may present viewpoints that are in conflict. 
Attempts could be made to provide names that are prone to drug interactions to account for 
foreseeable friction among pledge class members. This initiative would likely afford students (givers and 
receivers of DTNs) more practice in recognizing drug interaction potential. Deviations can also be made 
from primarily focusing upon drug names, to broadening the field to notable monitoring parameters, e.g., 
laboratory markers, and commonly reported side effects to drug therapies. These variations could 
presumably compel students to further investigate why these manifestations are likely to occur. Lastly, 
research could be devised to evaluate outcomes of interest, e.g., academic performances within pharmacy 
curriculums, between pharmacy students that are members of this organization operating within this drug 
climate versus those without such affiliation. 
. 
Conclusion 
Extracurricular processes have the tendency to impart life skills that translate into memorable 
learning experiences for pharmacy students. Coupling societal practicalities with educational precepts can 
lead to satisfying self-discoveries. Engineering activities that empower pharmacy students to be catalysts 
in their own scholastic fulfilment epitomizes a routine that gives rise to success. Invoking widespread 
collaboration among pharmacy students through longitudinal investments in each other’s academic 
prowess will retain a pharmacy profession galvanized by individual and collective advancement. 
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Table 1: Drug Therapy Names/Aspects (Spring 2004 – Spring 2008) 
2004 
 
□ DoC∩ □ Strong Start □ Alteplase □ Metamucil □ LSD† □ ----- □ Propanolol □ 
Mellaril         □ Namenda  □ Zithromax □ Miralax □ Aricept □ Ambien □ Clonidine 
□ Ziprasidone               □ Mylanta □ Depakote □  Rifampin □ Cialis □ Panax 
quinquefolius □ Lomotil □ Gentamicin  □ Cardizem LA‡ □ Colace □ Abilify 
2005 
 
□ ----- □ ADR* □ Nexium □ Loperamide □ Miralax □ ----- □ Haloperidol  
□ Cyclobenzaprine □ Compazine □ Digoxin □ Ritonavir □ J&J+ Baby Shampoo □ --
---           □ Dexedrin Spanules □ Strattera □ Ginseng 
2006 
 
□ Deltasone □ Rifabutin □ Aspirin □ Penicillin □ Yasmin □ Potassium Chloride                      
□ Metoprolol ERǁ □ Doxorubicin □ Robitussin □ No Doz □ Premarin □ Niacin □ 
Multivitamins □ Hydroxyzine □ Nitrous Oxide □ Mineral Oil □ Inspra □ Ginkgo 
bilboa          □ Yohimbine □ Sertraline □ Cannabis □ ----- □ Lorazepam □ Naloxone  
□ Mucinex 
2007 
 
□ Placebo □ Vancomycin □ Byetta □ Camomile □ HCTZǂ □ Fosphenytoin □ Inomax 
□ Trizivir □ Paxil □ Crestor □ Diltiazem □ ----- □ Inderal LA‡ □ Carafate 
2008 
 
□ Phenobarbital □ Norepinephrine □ ----- □ Nitroquick □ Clonidine □ 
Hydromorphone            □ Valerian Root □ ----- □ Zidovudine □ Promethazine □ 
Donepezil 
 
Key: ∩: Drug of Choice; †: Lysergic acid diethylamide; ‡: Long Acting; *: Adverse 
Drug Reaction +: Johnson & Johnson; ǁ: Extended Release; ǂ: Hydrochlorothiazide;                               
-----: Discontinued process; Italics: Recurrent drug therapies 
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Table 2: Drug Therapy Names/Aspects (Spring 2009 – Spring 2014) 
2009 
□ Ultram □ Sumatriptan □ Vioxx↕ □ Lantus □ Venlafaxine □ Epi Pen □ Kapidex □ 
Provigil 
□ Escitalopram □ Lavendar □ Tussionex □ Colgate □ Ecstasy MDMA∩ □ 
Methylphenidate 
□ Versed □ Clonazepam □ Methyldopa □ Vaccine □ Konsyl □ KY Jelly 
2010 
□ Atropine □ Skelaxin □ Concerta □ Thiamine □ Zoloft □ Lasix SR‡ □ Ziprasidone                   
□ Leucovorin □ Nuvigil □ Chaste Berry □ Plavix □ Dopamine □ Actos □ 
Fluphenazine           □ Prozac □ Risperidone 
2011 
□ Serotonin □ Vivarin  □ Celexa □ Nitroglycerin □ Insulin □ Bambuterol# □ Librium               
□ Eskalith □ Grandaxin# □ Fusilev □ St. John’s Wort □ Coumadin □ Diazepam  
2012 
□ Paroxetine □ Klonopin □ Cuprimine □ ----- □ Nudexta □ Intuniv □ ----- □ AndroFire 
2013 
□ Bromazepam □ Focalin XR* □ Seroquel □ Daytrana □ Oxytocin □ Tamiflu □ 
Zyprexa           □ Ketamine □ Psyllium □ Forteo □ PRN† □ Medrol Dosepack □ ----- 
□ ----- □ Kynamro  
2014 
□ Fioricet □ Cordarone □ Clozapine □ Romazicon □ Isoniazid □ Catapres □ 
Chloroquine 
□ Restasis □ Tagamet □ Viagra □ Ethanol □ Dexamethasone □ Flexeril □ Namenda 
 
Key: ∩: 3,4-Methylenedioxymethamphetamine; ‡: Sustained Release; *: Extended 
Release;  
†: As needed; -----: Discontinued process; Italics: Recurrent drug therapies;                                 
↕: Removed from U.S.A. market; #: Not available in U.S.A. market 
 
